How to deal with adverse reactions caused by capmatinib?

is an oral MET inhibitor, mainly used to treat advanced non-small cell lung cancer (NSCLC) carrying MET gene exon 14 skipping mutations. Capmatinib has a relatively good therapeutic effect, but it may also be accompanied by some adverse reactions during use, which can be relieved by adjusting the dose or drug intervention under the guidance of a doctor.

Adverse reaction treatment methods

1. Peripheral edema: Peripheral edema is one of the common side effects of capmatinib treatment. Management includes elevating the affected limb, wearing compression stockings, and reducing sodium intake. If edema seriously affects daily activities, treatment may need to be suspended and the treatment plan adjusted under the guidance of a doctor.

2. Nausea and vomiting: Nausea and vomiting are also problems that patients may encounter. In order to alleviate these symptoms, doctors may recommend that patients maintain good eating habits and avoid greasy and spicy foods during medication, and provide corresponding pharmaceutical support, such as anti-nausea drugs, according to the patient's condition.

3. Diarrhea: Diarrhea is another common adverse reaction. Managing diarrhea often requires modifying your diet to increase your intake of easily digestible foods while maintaining adequate fluids. In some cases, antidiarrheal medications may be needed.

4. Fatigue: Fatigue may affect the patient's quality of daily life. Ways to manage fatigue include getting enough rest, balancing daily activities, and possibly physical therapy. When necessary, the dose of capmatinib should be reduced or treatment should be temporarily interrupted based on the severity of adverse reactions.

5. Abnormal liver function: Capmatinib may cause an increase in liver function indicators such as ALT and AST. Liver function tests are necessary before and regularly during treatment. If hepatotoxicity occurs, dose adjustment or treatment suspension may be necessary based on the severity of injury.

6. Interstitial lung disease (ILD)/pneumonitis: This is a potentially serious side effect that may be life-threatening. Patients should be informed to monitor for new or worsening pulmonary symptoms, such as dyspnea, cough, or fever. Once these symptoms occur, capmatinib should be discontinued immediately and treated with antibiotics and other drugs under the guidance of a physician.

7. Photosensitivity: Capmatinib may increase the patient's sensitivity to light. Patients are advised to take steps to prevent UV exposure, such as using sunscreen and wearing protective clothing.

Capmatinib, as a potent MET inhibitor, plays an important role in the treatment of non-small cell lung cancer. However, its adverse reactions need to be controlled through appropriate management and doctor's guidance. Patients should fully understand the possible side effects and communicate with their doctors in a timely manner if any problems arise. With appropriate dose adjustments, lifestyle changes, and medical intervention, most adverse reactions can be effectively managed, allowing patients to continue to benefit from capmatinib treatment.